Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics’ U.S. subsidiary (Samsung Biologics America) has decided on a shareholder-directed rights offering of approximately KRW 524.9B to fund the acquisition of Human Genome Sciences in Rockville, U.S., and cover operating expenses.
📊 [Key Disclosure Details & Financial Summary]
- Subsidiary Information:
- Subsidiary Name: Samsung Biologics America, Inc. (100% owned subsidiary)
- CEO: Yong-Hwan Jin
- Core Business: Biopharmaceutical development and other business support services
- Capital Increase & Use of Proceeds:
- Type and Number of New Shares: 350,000 common shares
- Total Shares Issued Prior to Increase: 10,000 common shares
- Issue Price Per Share: KRW 1,499,700 (USD 1,000, FX rate USD/KRW 1,499.70 as of March 20, 2026)
- Total Amount Raised: KRW 524.895B / KRW 524,895,000,000 (USD 350,000,000)
- Use of Proceeds (Amounts subject to final confirmation):
- Acquisition of Other Corporate Securities: KRW 484.403B / KRW 484,403,100,000 (USD 323,000,000, subject to final confirmation)
- Operating Funds: KRW 40.492B / KRW 40,491,900,000 (USD 27,000,000, subject to final confirmation)
- Method of Rights Offering: Shareholder-allocated rights offering
- Key Schedule & Terms:
- Record Date for New Share Allocation & Payment Date: 2026-03-27
- New Shares Allocated Per Existing Share: 35 shares
- Board Resolution Date: 2026-03-20
- Other Key Notes:
- The rights offering is conducted to secure funds for acquiring Human Genome Sciences located in Rockville, U.S., and for working capital.
- The specific breakdown of amounts for use of proceeds (operating funds and acquisition of securities) will be finalized at a later date.
- As an overseas unlisted entity, the subsidiary is exempt from submitting a securities registration statement.
- Financial amounts and schedules are subject to change during the execution process.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Capital Rights Offering Payment Completion
This filing is a disclosure regarding a subsidiary’s rights offering to finance a U.S. corporate acquisition and operational expenses. Confirming whether the capital payment is completed as scheduled on the payment date (March 27, 2026) is important for verifying the subsidiary’s funding execution and transaction progress. Details can be verified in upcoming periodic reports and subsequent disclosures.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
